Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | PARL | Q9H300 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652576 | 0.86 | KMT2A (0.45) | KMT2AMEN1CRHBPGFERCRHR2 | |
| SCHEMBL5650754 | 0.86 | KMT2A (0.45) | KMT2AMEN1CRHBPGFERCRHR2 | |
| SCHEMBL27959334 | 0.81 | SIRT6 (0.50) | KMT2AMEN1LMNAALDH1A1SIRT6 | |
| SCHEMBL27959335 | 0.81 | SIRT6 (0.50) | KMT2AMEN1LMNAALDH1A1SIRT6 | |
| SCHEMBL30912424 | 0.81 | KMT2A (0.46) | KMT2AMEN1CRHBPGFERCRHR2 | |
| SCHEMBL30912496 | 0.81 | KMT2A (0.46) | KMT2AMEN1CRHBPGFERCRHR2 | |
| SCHEMBL9893023 | 0.79 | PER2 (0.46) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL9893157 | 0.79 | PTGER2 (0.42) | — | |
| SCHEMBL9892975 | 0.79 | PTGER2 (0.44) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9892982 | 0.78 | PTGS2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | KMT2A 3551/4885MEN1 4874/4885GSK3A 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.